- Another Paragon offshoot chooses reverse merger, this time for migraine drugsThey say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the…Endpoints · 2mo ago↗ source
- Acceleron leaders and Westlake jumpstart new IPF biotechAfter success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A roun…Endpoints · 2mo ago↗ source
- BioMarin drug acquired in buyout misses goal in rare disease study<figure><div><img src="https://imgproxy.divecdn.com/eghZalcvmA2hgw6MaT-fv8r1ksNzwZmQfKmkMEAO6pE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjg5Nzg0NjQwLmpwZ…